Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.

Xiuman ZhouJiangfeng DuHongfei WangChunxia ChenLing JiaoXiangrui ChengXiaowen ZhouShaomeng ChenShanshan GouWenshan ZhaoWenjie ZhaiJunhui ChenYan-Feng Gao

Published in: Cell communication and signaling : CCS (2020)

A small molecule liothyronine was discovered to serve as a potential candidate for cancer immunotherapy by blocking the immune checkpoint TIGIT/PVR. Video abstract.

Keyphrases

small molecule
protein protein
risk assessment